
    
      This was a Phase 2, multicenter, open-label, sequential, dose-finding trial designed with up
      to 12 treatment cohorts of 15 participants per cohort. Each participant received an
      intravenous dose of peginesatide administered once every 4 weeks (Q4W) for a total of 6
      doses. Dosage regimens varied by cohort. Participants were followed for a minimum of 42 days
      after the last administration of peginesatide.
    
  